Prudential Financial Inc Aeglea Bio Therapeutics, Inc. Transaction History

Prudential Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $6,020 - $26,488	17,200 New	17,200 $0
Q3 2020 Nov 16, 2020	SELL	$6.51 - $9.33 $62,183 - $89,120	-9,552 Reduced 37.7%	15,788 $112,000
Q2 2020 Aug 12, 2020	SELL	$4.01 - $11.04 $20,952 - $57,683	-5,225 Reduced 17.09%	25,340 $234,000
Q1 2020 May 12, 2020	SELL	$3.51 - $8.48 $11,232 - $27,136	-3,200 Reduced 9.48%	30,565 $142,000
Q4 2019 Feb 11, 2020	SELL	$7.23 - $8.55 $1,446 - $1,710	-200 Reduced 0.59%	33,765 $257,000
Q3 2019 Nov 13, 2019	BUY	$6.42 - $9.0 $66,511 - $93,240	10,360 Added 43.89%	33,965 $261,000
Q2 2019 Aug 08, 2019	BUY	$6.1 - $8.78 $143,990 - $207,251	23,605 New	23,605 $0

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.